Trial · NCT03196180
Results by group27
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 27
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Feasibility of Intravaginal Use 5-FU and Imiquimod on Alternating Weeks in Women With Biopsy Confirmed High Grade Cervical Squamous Intraepithelial Lesions. | Treatment (Topical Fluorouracil, Imiquimod) | Safety | 4 | Participants | |
| Feasibility of Intravaginal Use 5-FU and Imiquimod on Alternating Weeks in Women With Biopsy Confirmed High Grade Cervical Squamous Intraepithelial Lesions. | Treatment (Topical Fluorouracil, Imiquimod) | Tolerability | 1 | Participants | |
| Response to Intravaginal 5-FU and Imiquimod Defined as Histologic Regression and Clearance of High-risk Human Papilloma Virus (HR-HPV) | Treatment (Topical Fluorouracil, Imiquimod) | 40 | 95% Confidence Interval 12 to 74 | percentage of participants | |
| Type Specific Human Papillomavirus (HPV) Clearance | Treatment (Topical Fluorouracil, Imiquimod) | HPV16 | 75 | 95% Confidence Interval 19 to 99 | percentage of participants |
| Type Specific Human Papillomavirus (HPV) Clearance | Treatment (Topical Fluorouracil, Imiquimod) | HPV31 | 50 | 95% Confidence Interval 1 to 99 | percentage of participants |
| Type Specific Human Papillomavirus (HPV) Clearance | Treatment (Topical Fluorouracil, Imiquimod) | HPV35 | 100 | 95% Confidence Interval 3 to 100 | percentage of participants |
| Type Specific Human Papillomavirus (HPV) Clearance | Treatment (Topical Fluorouracil, Imiquimod) | HPV39 | 0 | 95% Confidence Interval 0 to 98 | percentage of participants |
| Type Specific Human Papillomavirus (HPV) Clearance | Treatment (Topical Fluorouracil, Imiquimod) | HPV51 | 0 | 95% Confidence Interval 0 to 84 | percentage of participants |
| Type Specific Human Papillomavirus (HPV) Clearance | Treatment (Topical Fluorouracil, Imiquimod) | HPV52 | 75 | 95% Confidence Interval 19 to 99 | percentage of participants |
| Type Specific Human Papillomavirus (HPV) Clearance | Treatment (Topical Fluorouracil, Imiquimod) | HPV56 | 0 | 95% Confidence Interval 0 to 98 | percentage of participants |
| Type Specific Human Papillomavirus (HPV) Clearance | Treatment (Topical Fluorouracil, Imiquimod) | HPV66 | 50 | 95% Confidence Interval 1 to 99 | percentage of participants |
| Type Specific Human Papillomavirus (HPV) Clearance | Treatment (Topical Fluorouracil, Imiquimod) | HPV68 | 100 | 95% Confidence Interval 16 to 100 | percentage of participants |
| Change in Expression of Biomarkers of Local Immune Activation (Cytokines) After Treatment With Self-administered Intravaginal Topical Fluorouracil and Imiquimod | Treatment (Topical Fluorouracil, Imiquimod) | IFN-alpha 2 | -0.29 | Standard Deviation 1.49 | log pg/ml |
| Change in Expression of Biomarkers of Local Immune Activation (Cytokines) After Treatment With Self-administered Intravaginal Topical Fluorouracil and Imiquimod | Treatment (Topical Fluorouracil, Imiquimod) | IFN-gamma | 0.16 | Standard Deviation 0.81 | log pg/ml |
| Change in Expression of Biomarkers of Local Immune Activation (Cytokines) After Treatment With Self-administered Intravaginal Topical Fluorouracil and Imiquimod | Treatment (Topical Fluorouracil, Imiquimod) | IL-1 alpha | -0.55 | Standard Deviation 1.01 | log pg/ml |
| Change in Expression of Biomarkers of Local Immune Activation (Cytokines) After Treatment With Self-administered Intravaginal Topical Fluorouracil and Imiquimod | Treatment (Topical Fluorouracil, Imiquimod) | IL-1 beta | -0.15 | Standard Deviation 1.84 | log pg/ml |
| Change in Expression of Biomarkers of Local Immune Activation (Cytokines) After Treatment With Self-administered Intravaginal Topical Fluorouracil and Imiquimod | Treatment (Topical Fluorouracil, Imiquimod) | IL-6 | -0.84 | Standard Deviation 1.94 | log pg/ml |
| Change in Expression of Biomarkers of Local Immune Activation (Cytokines) After Treatment With Self-administered Intravaginal Topical Fluorouracil and Imiquimod | Treatment (Topical Fluorouracil, Imiquimod) | IL-8 | -0.16 | Standard Deviation 2.63 | log pg/ml |
| Change in Expression of Biomarkers of Local Immune Activation (Cytokines) After Treatment With Self-administered Intravaginal Topical Fluorouracil and Imiquimod | Treatment (Topical Fluorouracil, Imiquimod) | IL-12 | 0.15 | Standard Deviation 0.95 | log pg/ml |
| Change in Expression of Biomarkers of Local Immune Activation (Cytokines) After Treatment With Self-administered Intravaginal Topical Fluorouracil and Imiquimod | Treatment (Topical Fluorouracil, Imiquimod) | IL-13 | -0.53 | Standard Deviation 1.11 | log pg/ml |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03196180/results